Core Insights - Tirzepatide has been shown to reduce the risk of developing diabetes by 94% in prediabetic patients compared to those taking a placebo [3][5] - A study comparing Tirzepatide and Semaglutide indicates that Tirzepatide may be more effective for weight loss in overweight or obese adults [6][14] Group 1: Tirzepatide Efficacy - In a study tracking over 1,000 overweight or obese prediabetic individuals, those taking Tirzepatide lost nearly 20% of their body weight compared to placebo [5] - The drug targets GLP-1 and GIP hormones, helping to regulate blood sugar levels and appetite [5] - Approximately 81.8% of participants on Tirzepatide lost at least 5% of their body weight, compared to 66.5% on Semaglutide, with a risk ratio of 1.76 [11][13] Group 2: Comparative Study Results - The study included 18,386 participants, with an average follow-up of 165 days, and found similar gastrointestinal adverse event risks between both drug groups [8] - Weight loss percentages at different intervals showed Tirzepatide outperforming Semaglutide: 5.9% vs. 3.6% at 3 months, 10.1% vs. 5.8% at 6 months, and 15.3% vs. 8.3% at 12 months [13] - The findings contribute valuable data for understanding the effectiveness of these weight loss medications and may influence future clinical guidelines [14]